Insulin Injection Sites for Diabetes

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byJordanna Kapeluto, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of British Columbia

No Placebo Group

Trial Summary

What is the purpose of this trial?Evaluation of insulin absorption at sites affected by clinically apparent lipohypertrophy through short-term continuous glucose monitoring has shown inconsistent results and it is yet unknown how or if subclinical lipohypertrophy affects absorption. In this study investigators propose to enroll at least 20 people who participated in phase 1 and who were determined to have subclinical lipohypertrophy to examine the correlation between glycemic control and amount of insulin injected in subclinical hypertrophic areas using capillary blood glucose and continuous glucose monitoring.

Eligibility Criteria

This trial is for people over 19 who have had Type 1 or Type 2 diabetes for at least two years and are using insulin. They must have been part of phase 1 of the study and identified with subclinical lipohypertrophy. Those on certain diabetes medications, steroids, or unable to communicate in English without a translator cannot join.

Inclusion Criteria

I am 19 years old or older.

I have been diagnosed with diabetes for at least 2 years.

Participation in phase 1

+1 more

Exclusion Criteria

Not fluent in speaking and writing English (unless accompanied by a translator)

I am currently taking injectable diabetes medications.

I am taking medication to increase my body's insulin production.

+1 more

Participant Groups

The study is looking into how well insulin is absorbed in areas affected by subclinical lipohypertrophy—a kind of localized swelling due to repeated injections. At least 20 participants will use continuous glucose monitoring to see if there's a link between their blood sugar control and the amount of insulin injected into these swollen spots.

2Treatment groups

Experimental Treatment

Group I: Normal Subcutaneous TissueExperimental Treatment1 Intervention

Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.

Group II: LipohypertrophyExperimental Treatment1 Intervention

Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.